Description
LIPUM AB is a Swedish clinical-phase biopharmaceutical company based in Umeå developing treatments for chronic inflammatory diseases. Its candidate SOL-116 is a humanized monoclonal antibody blocking BSSL (Bile Salt-Stimulated Lipase), a previously overlooked key molecule in inflammation. Successfully completed Part 1 of Phase I clinical trial with good safety profile. Listed on Nasdaq First North Growth Market.